Acambis is a developer of vaccines against infectious diseases. As a fully
integrated biotechnology company, it is capable of taking new vaccines from
early-stage research through to sales of the approved product. Its employees are
based at facilities in Cambridge, UK, Cambridge and Canton, MA, US, Miami, FL,
US and Toronto, Canada.
Like most biotechnology companies, Acambis started life as a research-focused
organisation. Today, it is looking to establish itself as one of the worlds
leading vaccine companies, with existing product sales, a strong pipeline of
products in development and research projects that will drive longer-term
growth.
Acambis was established in 1992 in the UK as Peptide Therapeutics Limited and
floated on the London Stock Exchange in November 1995. It listed its shares in
the form of ADRs on NASDAQ in February 2001.
In May 1999, it acquired a US-based vaccine research company, OraVax, Inc.
and, in December 2000, was renamed Acambis plc.  ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2004%2f06%2f28%2f0001021231-04-000438.html#FIS_COMPANY_INFORMATION"